FDA Guidance on EpCAM-Positive Cell Reduction by Filters
Summary
The FDA has issued guidance concerning the reduction of EpCAM-positive cells by filters. This document provides information relevant to drug manufacturers and medical device makers.
What changed
The FDA has released a guidance document related to the reduction of EpCAM-positive cells using filters. The document, identified by FDA-2025-N-5996-0030, is intended to provide clarity and information to regulated entities.
This guidance is primarily relevant to drug manufacturers and medical device makers involved in processes where EpCAM-positive cell reduction is a factor. Compliance officers should review the document to understand any implications for their product development, manufacturing, or quality control processes, although specific actionable steps or deadlines are not detailed in the provided information.
Archived snapshot
Mar 19, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Content
Content Restricted
Reason Restricted: Copyrighted
Related changes
Get daily alerts for Regs.gov: Food and Drug Administration
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from FDA.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when Regs.gov: Food and Drug Administration publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.